Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05479578 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
A Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Adenocarcinoma, sponsored by Rashmi Verma, MD.
- Active
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT05479578 is a Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Adenocarcinoma that is active but no longer recruiting, run by Rashmi Verma, MD. The registered enrollment target is 7 participants, below the 78-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05479578, a Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by Rashmi Verma, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving low doses of cyclophosphamide daily may reduce side effects. Dexamethasone is a corticosteroid drug that is used to treat some of the problems caused by chemotherapy treatment. The combination of cyclophosphamide and dexamethasone may work better in treating patients with castration resistant prostate cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05479578
The ClinicalTrials.gov registry entry for NCT05479578 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (91% lower). The listed sponsor is Rashmi Verma, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT05479578 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05479578 about?
NCT05479578 is a clinical study titled "Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer". This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide, work in different ways to ...
What is the current status of trial NCT05479578?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-06-29. Estimated completion is 2025-05-01.
What conditions does trial NCT05479578 study?
This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8.
What interventions are being tested in trial NCT05479578?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05479578?
This trial is sponsored by Rashmi Verma, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05479578 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-Resistant Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
RECRUITING · Phase 1
-
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RECRUITING · Phase 1
-
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using 18F-TRX
RECRUITING · Phase 1
Explore more on PlainTrial
Castration-Resistant Prostate Carcinoma
All registered trials for this condition
Metastatic Prostate Adenocarcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.